TrialBMC cancer2024

Anlotinib alone or in combination with bevacizumab in the treatment of recurrent high-grade glioma: a prospective single-arm, open-label phase II trial.

Shuangshuang Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.